Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study

Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study

Abstract Background and Aim This study aimed to clarify the efficacy and safety of oral semaglutide treatment in patients with non‐alcoholic fatty liver disease (NAFLD) complicated by type 2 diabetes mellitus (T2DM). Methods This was a single‐arm, open‐label pilot study. Sixteen patients with NAFLD...

Full description

Bibliographic Details
Main Authors: Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Hirotaka Ono, Tadamichi Kawano, Yuji Yoshida, Tomomi Okubo, Korenobu Hayama, Ai Nakagawa‐Iwashita, Norio Itokawa, Chisa Kondo, Mototsugu Nagao, Katsuhiko Iwakiri
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:JGH Open
Subjects:
controlled attenuation parameter
GLP‐1 receptor agonists
liver fibrosis
non‐alcoholic fatty liver disease
semaglutide
Online Access:https://doi.org/10.1002/jgh3.12780

Internet

https://doi.org/10.1002/jgh3.12780

Similar Items